Suprallay™ is a consumer-worn device that utilizes a sensor inserted under the patient’s skin. Leveraging our proprietary RapiCheck™ technology, Suprallay monitors both neuro-transmitted pain signals as well as blood-based drug concentration levels to help patients reduce their dependence on opioids to manage chronic pain. One feature of Suprallay is that it connects to a patient’s smart phone to provide the patient with critical notifications as well as treatment support.

Via the smart phone connection, Suprallay also transmits data back to AalertMed’s central servers, feeding a web-based provider portal and related electronic health records that allow a patient’s healthcare provider to monitor patient condition. Notably, the system is designed to alert a health care provider when one of their patients is experiencing a significant pain event that is not being effectively controlled through medication OR when the sensors detect a measurable presence of both opioids and benzodiazepines (or ‘benzos’) in the patient’s blood.

This ability to detect, report and alert for these two substances is game-changing technology in the battle against opioid-related overdoses and deaths. While studies vary, the combination of opioids and benzos leads to a significantly increased risk of overdose death as compared with patients using an opioid-only treatment approach.